Karen H. Vousden

71.8k total citations · 24 hit papers
240 papers, 49.2k citations indexed

About

Karen H. Vousden is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Karen H. Vousden has authored 240 papers receiving a total of 49.2k indexed citations (citations by other indexed papers that have themselves been cited), including 171 papers in Oncology, 164 papers in Molecular Biology and 63 papers in Cancer Research. Recurrent topics in Karen H. Vousden's work include Cancer-related Molecular Pathways (162 papers), Ubiquitin and proteasome pathways (55 papers) and Cancer Research and Treatments (51 papers). Karen H. Vousden is often cited by papers focused on Cancer-related Molecular Pathways (162 papers), Ubiquitin and proteasome pathways (55 papers) and Cancer Research and Treatments (51 papers). Karen H. Vousden collaborates with scholars based in United Kingdom, United States and Belgium. Karen H. Vousden's co-authors include Patricia Müller, Michael H.G. Kubbutat, Gérard I. Evan, Xin Lü, Carol Prives, Eric C. Cheung, Stephen N. Jones, David P. Lane, Robert L. Ludwig and Kevin M. Ryan and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Karen H. Vousden

235 papers receiving 48.4k citations

Hit Papers

Regulation of p53 stability by Mdm2 1989 2026 2001 2013 1997 2001 2002 2009 2007 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Regulation of p53 stability by Mdm2
    1997 2.8k citations Karen H. Vousden et al. Nature profile →
  2. Proliferation, cell cycle and apoptosis in cancer
    2001 2.8k citations Gérard I. Evan, Karen H. Vousden Nature profile →
  3. Live or let die: the cell's response to p53
    2002 2.6k citations Karen H. Vousden et al. profile →
  4. Blinded by the Light: The Growing Complexity of p53
    2009 2.5k citations Karen H. Vousden et al. profile →
  5. p53 in health and disease
    2007 1.8k citations Karen H. Vousden et al. profile →
  6. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
    2006 1.6k citations Karen H. Vousden et al. profile →
  7. p53 mutations in cancer
    2012 1.3k citations Karen H. Vousden et al. profile →
  8. Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
    2014 1.1k citations Karen H. Vousden et al. profile →
  9. The role of ROS in tumour development and progression
    2022 1.1k citations Eric C. Cheung, Karen H. Vousden profile →
  10. Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
    2000 874 citations Jane P. Jensen, Robert L. Ludwig et al. profile →
  11. p53 in survival, death and metabolic health: a lifeguard with a licence to kill
    2015 831 citations Karen H. Vousden et al. profile →
  12. p53 and metabolism
    2009 780 citations Karen H. Vousden, Kevin M. Ryan profile →
  13. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.
    1989 772 citations Karen H. Vousden, Douglas R. Lowy et al. profile →
  14. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
    2012 745 citations Oliver D.K. Maddocks, Susan Mason et al. Nature profile →
  15. Serine and one-carbon metabolism in cancer
    2016 711 citations Karen H. Vousden et al. profile →
  16. p53
    2000 683 citations Karen H. Vousden profile →
  17. Mutant p53 Drives Invasion by Promoting Integrin Recycling
    2009 641 citations Natalia Lukashchuk, Robert L. Ludwig et al. profile →
  18. Role for the p53 homologue p73 in E2F-1-induced apoptosis
    2000 592 citations Karen H. Vousden et al. Nature profile →
  19. Regulation of HDM2 activity by the ribosomal protein L11
    2003 521 citations Marion Lohrum, Robert L. Ludwig et al. profile →
  20. Serine is a natural ligand and allosteric activator of pyruvate kinase M2
    2012 497 citations Oliver D.K. Maddocks, Karen H. Vousden et al. Nature profile →
  21. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
    2000 442 citations Karen H. Vousden, Tim Crook et al. profile →
  22. Serine, but Not Glycine, Supports One-Carbon Metabolism and Proliferation of Cancer Cells
    2014 441 citations Karen H. Vousden, Oliver D.K. Maddocks et al. profile →
  23. Modulating the therapeutic response of tumours to dietary serine and glycine starvation
    2017 420 citations Oliver D.K. Maddocks, Dimitris Athineos et al. Nature profile →
  24. Serine Metabolism Supports the Methionine Cycle and DNA/RNA Methylation through De Novo ATP Synthesis in Cancer Cells
    2016 322 citations Oliver D.K. Maddocks, Karen H. Vousden et al. Molecular Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen H. Vousden United Kingdom 105 34.6k 24.4k 12.3k 5.6k 4.7k 240 49.2k
Wafik S. El‐Deiry United States 100 32.9k 1.0× 23.2k 1.0× 9.3k 0.8× 3.1k 0.6× 4.7k 1.0× 584 46.9k
Moshe Oren Israel 116 34.9k 1.0× 28.8k 1.2× 9.9k 0.8× 2.6k 0.5× 7.2k 1.5× 323 48.9k
Michael B. Kastan United States 77 30.5k 0.9× 18.4k 0.8× 8.3k 0.7× 2.9k 0.5× 3.0k 0.6× 156 39.1k
Scott W. Lowe United States 123 50.1k 1.4× 23.0k 0.9× 16.9k 1.4× 4.2k 0.8× 4.0k 0.8× 325 69.6k
Anirban Maitra United States 115 26.6k 0.8× 25.8k 1.1× 14.4k 1.2× 5.5k 1.0× 1.3k 0.3× 564 51.1k
Charles J. Sherr United States 96 39.2k 1.1× 30.4k 1.2× 6.9k 0.6× 3.1k 0.5× 3.3k 0.7× 271 58.0k
William G. Kaelin United States 117 35.6k 1.0× 14.8k 0.6× 22.6k 1.8× 2.4k 0.4× 2.5k 0.5× 246 50.2k
Jiří Bártek Denmark 107 41.7k 1.2× 23.3k 1.0× 9.5k 0.8× 2.3k 0.4× 1.6k 0.3× 383 54.0k
J. Wade Harper United States 120 48.8k 1.4× 19.5k 0.8× 7.1k 0.6× 9.5k 1.7× 2.0k 0.4× 307 62.5k
Carlos Cordon‐Cardo United States 129 41.4k 1.2× 22.8k 0.9× 12.8k 1.0× 2.8k 0.5× 2.5k 0.5× 564 68.1k

Countries citing papers authored by Karen H. Vousden

Since Specialization
Citations

This map shows the geographic impact of Karen H. Vousden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen H. Vousden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen H. Vousden more than expected).

Fields of papers citing papers by Karen H. Vousden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen H. Vousden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen H. Vousden. The network helps show where Karen H. Vousden may publish in the future.

Co-authorship network of co-authors of Karen H. Vousden

This figure shows the co-authorship network connecting the top 25 collaborators of Karen H. Vousden. A scholar is included among the top collaborators of Karen H. Vousden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen H. Vousden. Karen H. Vousden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lima, Ana, Sian-Tsung Tan, Aida Di Gregorio, et al.. (2025). Sensing of extracellular l -proline availability by the integrated stress response determines the outcome of cell competition. Science Advances. 11(28). eadw1883–eadw1883.
2.
Cheung, Eric C., Dimitris Athineos, Mark Hughes, et al.. (2025). p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis. JHEP Reports. 7(7). 101397–101397. 1 indexed citations
3.
Lewis, Samantha C., Alexis A. Jourdain, Brenda A. Schulman, et al.. (2024). Recovering from the stress of the COVID-19 pandemic. Molecular Cell. 84(1). 8–11.
4.
Tripathi, Brajendra K., Xiaolan Qian, Marian E. Durkin, et al.. (2024). The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export. Nature Cancer. 5(12). 1902–1918. 1 indexed citations
5.
Papalazarou, Vassilis, Alice C. Newman, Alejandro Huerta Uribe, et al.. (2023). Phenotypic profiling of solute carriers characterizes serine transport in cancer. Nature Metabolism. 5(12). 2148–2168. 22 indexed citations
6.
Zani, Fabio, Julianna Blagih, Tim Gruber, et al.. (2023). The dietary sweetener sucralose is a negative modulator of T cell-mediated responses. Nature. 615(7953). 705–711. 69 indexed citations
7.
Humpton, Timothy J., Andreas Hock, Christos Kiourtis, et al.. (2022). A noninvasive iRFP713 p53 reporter reveals dynamic p53 activity in response to irradiation and liver regeneration in vivo. Science Signaling. 15(720). eabd9099–eabd9099. 3 indexed citations
8.
Ahmed, Syed Feroj, Gary Sibbet, Ventzislava A. Hristova, et al.. (2020). Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain. Nature Communications. 11(1). 2094–2094. 28 indexed citations
9.
Humpton, Timothy J., Gina M. DeNicola, Dan Lü, et al.. (2019). Oncogenic KRAS Induces NIX-Mediated Mitophagy to Promote Pancreatic Cancer. Cancer Discovery. 9(9). 1268–1287. 139 indexed citations
10.
Walton, Josephine, Julianna Blagih, Darren Ennis, et al.. (2016). CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. Cancer Research. 76(20). 6118–6129. 150 indexed citations
11.
Haller, Martina, Andreas Hock, Evangelos Giampazolias, et al.. (2014). Ubiquitination and proteasomal degradation of ATG12 regulates its proapoptotic activity. Autophagy. 10(12). 2269–2278. 48 indexed citations
12.
Vigneron, Arnaud, et al.. (2011). MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle. 10(18). 3176–3188. 47 indexed citations
13.
Vousden, Karen H.. (2009). Partners in death: a role for p73 and NF-kB in promoting apoptosis. Aging. 1(3). 275–277. 14 indexed citations
14.
Lukashchuk, Natalia & Karen H. Vousden. (2007). Ubiquitination and Degradation of Mutant p53. Molecular and Cellular Biology. 27(23). 8284–8295. 180 indexed citations
15.
Yang, Yili, Jirouta Kitagaki, Ren‐Ming Dai, et al.. (2007). Inhibitors of Ubiquitin-Activating Enzyme (E1), a New Class of Potential Cancer Therapeutics. Cancer Research. 67(19). 9472–9481. 372 indexed citations
16.
Lohrum, Marion, Douglas Woods, Robert L. Ludwig, Éva Bálint, & Karen H. Vousden. (2001). C-Terminal Ubiquitination of p53 Contributes to Nuclear Export. Molecular and Cellular Biology. 21(24). 8521–8532. 195 indexed citations
17.
Li, Jian Jian, J. S. Rhim, Richard Schlegel, Karen H. Vousden, & Nancy H. Colburn. (1998). Expression of dominant negative Jun inhibits elevated AP-1 and NF-κB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene. 16(21). 2711–2721. 101 indexed citations
18.
Ludwig, Robert L., Stewart Bates, & Karen H. Vousden. (1996). Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic Function. Molecular and Cellular Biology. 16(9). 4952–4960. 228 indexed citations
19.
Crook, Tim, et al.. (1996). Sensitivity of p53 Lysine Mutants to Ubiquitin-Directed Degradation Targeted by Human Papillomavirus E6. Virology. 217(1). 285–292. 34 indexed citations
20.
Marshall, C. J., Karen H. Vousden, & Brad Ozanne. (1985). The involvement of activated ras genes in determining the transformed phenotype. Proceedings of the Royal Society of London. Series B, Biological sciences. 226(1242). 99–106. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wafik S. El‐Deiry Breakdown of academic impact, for papers by Moshe Oren Breakdown of academic impact, for papers by Michael B. Kastan Breakdown of academic impact, for papers by Scott W. Lowe Breakdown of academic impact, for papers by Anirban Maitra Breakdown of academic impact, for papers by Charles J. Sherr Breakdown of academic impact, for papers by William G. Kaelin Breakdown of academic impact, for papers by Jiří Bártek Breakdown of academic impact, for papers by J. Wade Harper Breakdown of academic impact, for papers by Carlos Cordon‐Cardo
Rankless by CCL
2026